Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates that hemostatic tough adhesives achieve consistent hemostasis, indicating potential improvements for trauma care and surgery.
Hemorrhage from internal organs remains a critical challenge in both trauma care and surgical procedures, as existing hemostatic adjuncts frequently fail to provide consistent and effective bleeding control, particularly under conditions of active bleeding or impaired coagulation. Here, we develop and evaluate a Hemostatic Tough Adhesive (HTA) in controlled preclinical models of traumatic solid organ injury and compare its performance against leading commercially available hemostatic agents. The HTA consistently outperformed its counterparts, achieving 100% hemostasis in both liver and spleen injuries within an in vivo preclinical porcine model. In contrast, existing adjuncts exhibited variable and often incomplete efficacy. Beyond immediate hemostasis, the HTA demonstrated prolonged stability and biocompatibility during the postoperative wound healing phase. Notably, the HTA exhibited tissue surface adhesion energy several orders of magnitude greater than that of current hemostatic products, indicating its potential utility for surgical and trauma-related bleeding management.
No takes yet. Share an insight, caveat, or question.
Kent et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: